Woodline Partners LP Purchases 29,266 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Woodline Partners LP grew its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 5.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 545,645 shares of the company's stock after purchasing an additional 29,266 shares during the quarter. Woodline Partners LP owned approximately 0.41% of Centessa Pharmaceuticals worth $9,140,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Centessa Pharmaceuticals by 40.1% during the fourth quarter. JPMorgan Chase & Co. now owns 190,385 shares of the company's stock worth $3,189,000 after acquiring an additional 54,482 shares during the period. OMERS ADMINISTRATION Corp bought a new position in Centessa Pharmaceuticals during the fourth quarter worth $171,000. Lazard Asset Management LLC bought a new position in Centessa Pharmaceuticals during the fourth quarter worth $1,225,000. Barclays PLC boosted its stake in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares in the last quarter. Finally, Diadema Partners LP acquired a new stake in Centessa Pharmaceuticals during the fourth quarter worth $2,209,000. Institutional investors own 82.01% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price target on the stock. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price target on the stock. Finally, Needham & Company LLC initiated coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday. They set a "buy" rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $27.89.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock traded up $0.01 during trading hours on Wednesday, reaching $12.78. 139,172 shares of the stock were exchanged, compared to its average volume of 648,651. The company has a market cap of $1.71 billion, a P/E ratio of -8.36 and a beta of 1.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The stock has a 50 day moving average of $12.91 and a two-hundred day moving average of $15.43.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. Equities analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Insider Activity

In other news, General Counsel Iqbal J. Hussain sold 2,080 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $14.01, for a total transaction of $29,140.80. Following the completion of the transaction, the general counsel now owns 105,386 shares of the company's stock, valued at approximately $1,476,457.86. The trade was a 1.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Arjun Goyal acquired 417,646 shares of the company's stock in a transaction dated Friday, May 16th. The shares were bought at an average cost of $12.73 per share, with a total value of $5,316,633.58. Following the purchase, the director now owns 462,585 shares of the company's stock, valued at approximately $5,888,707.05. This trade represents a 929.36% increase in their position. The disclosure for this purchase can be found here. Insiders sold 175,398 shares of company stock worth $2,551,442 in the last quarter. 7.09% of the stock is owned by corporate insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.